AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04973540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iron Bioresorbable Scaffold System (IBS Angel)
Description: Subjects in this arm will be implanted with IBS Angel.
Study NCT06243367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Patients were instructed to be fasting for 6 hours before surgery and received only placebo drink (200 ml clear water) two hours before surgery
Study NCT06243367 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate
Description: Patients were given a meal of cup of yogurt (100 ml) with 2 spoonful of honey (42 gm) at midnight before surgery and 200 ml of a clear carbohydrate drink on the day of surgery, 2 h before anesthesia induction. This drink consisted of 200 ml water in which two spoonful of honey were dissolved.
Study NCT06368895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation delivery through colonoscopy
Description: Patients will receive 4 L of macrogol and salts solution the afternoon before FMT and remain fasting the night before the scheduled treatment. During colonoscopy, about 350 mL of donor fecal preparation will be infused in the cecum.
Study NCT06368895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation delivery through oral capsules
Description: Intestinal gastro-resistant capsules (capacity 0.91 mL, overall 10\^8-9 bacteria per capsule) will be filled with the fecal slurry. From each donation weighing 100 g, it is expected to obtain 150 cps, which will be promptly frozen and stored at -80°C. At each monthly visit, the patient will receive 60 capsules, to be stored at -20°C at home. Capsules will be administered orally at the dose of 1 cps twice a day from month 1 post-colonoscopy to patients in the FMT group 1 (colonoscopy plus capsules), and from day 1 to patients in the FMT group 2 (capsules only).
Study NCT05253716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONS
Description: Immunonutritional supplement
Study NCT06428552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Daily rehabilitation program of 40 minutes duration using a mobile application to be completed 6 days per week for 12 weeks
Study NCT06059430 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05318248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidin
Description: 0,15mg Clonidin orally versus placebo pill
Study NCT05318248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill
Study NCT05622058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 administered in every chemotherapy treatment cycle as an IV infusion over 1 hour on Days 0 (approximately 18 hours prior to chemotherapy administration), 1 (approximately 1 hour prior to chemotherapy administration), and 2 (approximately 24 hours after the second infusion of ALRN-6924).
Study NCT05622058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Description: TAC will be administered as an IV infusion on Day 1 of every 3-week treatment cycle
Study NCT06097624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synchronized tele-exercise
Description: All evaluations and exercise interventions will be performed by via Google Meet, a video-conferencing application. The participation link will be sent to the individual by the researcher before each session. In case of any technological disruption, the session will be postponed to the nearest available time by phone. All interventions will be run by a blinded researcher.
Study NCT05172440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab combined with axitinib
Description: Subjects received axitinib 5 mg bid, 12 weeks, and tislelizumab 200 mg on the first day of the first week, 4th week, 7th week, and 10th week, and intravenous infusion. With 21 days as a treatment cycle, 4 cycles of treatment, namely 12 weeks. Axitinib was discontinued for 12 weeks after the completion of treatment, and surgery was performed 7 days later.
Study NCT06094660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic genicular nerve block
Description: Diagnostic block will be done with 1,5ml of Lidocaine 2% at the 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.
Study NCT06094660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with Radiofrequency Ablation (RFA)
Description: Genicular nerve block with RFA will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Radiofrequency ablation (RFA) is performed by creating two RFA lesions at the 3 treatment sites (6 lesions in total) after local anesthesia with 1,5ml lidocaine 2%. The lesions are made by heating the 5mm active tip of the needle to 80°C for 90 seconds.
Study NCT06094660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve block with Phenol 6%
Description: Genicular nerve block with Phenol 6% will be performed at 3 target sites: the superomedial, the superolateral and the inferomedial genicular nerve.~Chemical ablation with phenol is done by injection of 1 ,5ml of phenol 6 % at the 3 target sites after infiltration with contrast dye to rule out intravascular injection. Because infiltration with phenol is painless, prior infiltration of the target site with al local anaesthetic is not necessary.
Study NCT06470035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active VeNS Device
Description: Battery powered non-invasive neurostimulation device
Study NCT06470035 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VeNS Device
Description: Placebo comparator sham device (no active stimulation)
Study NCT04677751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Description: Participants will undergo 12 weeks of acupuncture therapy. There will be one 40 minute-1 hour. session per week.
Study NCT05367271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: 20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
Study NCT05367271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
Study NCT02414178 — intervention group
Intervention type: DRUG
Intervention: F 18 T807
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study NCT04910685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elenestinib
Description: Elenestinib oral tablet
Study NCT04910685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet
Study NCT04369131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Randomized placement of FES pads in one of four locations during each session. Locations include: (a) none, (b) calves only, (c) quads and abdominals only, and (d) calves, quads, and abdominals.
Study NCT05477524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA15
Description: Shot in the deltoid muscle (preferable in the nondominant arm)
Study NCT06344494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arch EchoTM Intracardiac Ultrasound catheter and ultrasound system
Description: Novel ICE catheter and combined ultrasound system
Study NCT06344494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOUNDSTAR 3D Diagnostic Ultrasound catheter and ACUSON P500 system
Description: Commercially available devices
Study NCT05477524 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Shot in the deltoid muscle (preferable in the nondominant arm)
Study NCT05241405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: QISENG
Description: 2 capsules/day for 8 weeks.
Study NCT05241405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 2 capsules/day for 8 weeks.
Study NCT06522282 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Emergency Stroke Unit based on 0.23-T MRI
Description: The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.
Study NCT06522282 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Standard stroke unit
Description: The participants with hyperacute ischemic stroke (arriving at the emergency department between 4.5-6 hours of symptom onset) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
Study NCT05462860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suprathel®
Description: Application of standard of care dressing.®
Study NCT05462860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suprathel®
Description: Application of standard of care dressing.®
Study NCT06246968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab as part of standard of care treatment.
Study NCT06246968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive Pembrolizumab as part of standard of care treatment.
Study NCT06246968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection.
Study NCT06414824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittently Scanned Continuous Glucose Monitoring
Description: FreeStyle Libre, 4 weeks
Study NCT06414824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Glucose Monitoring
Description: Standard blood glucose monitoring with glucose meters
Study NCT06234098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1965 Liposome Injection
Description: AT-1965 Liposome Injection administered intravenously once weekly for the first 3 weeks (Days 1, 8 and 15) of a 4 week cycle.
Study NCT05959096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC
Study NCT05959096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered IV
Study NCT04740034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 340
Description: AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells
Study NCT04181047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: Psychotherapy.
Study NCT04181047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.
Study NCT04181047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. TAU will NOT include electroconvulsive therapy or another trauma specific psychotherapy.
Study NCT06246123 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention will be administered.
Study NCT05579587 — intervention group
Intervention type: DEVICE
Intervention: Transoral Incisionless Fundoplication
Description: Transoral incisionless fundoplication (TIF) is a minimally invasive, endoscopic fundoplication technique. Transoral Incisionless Fundoplication (TIF) is an FDA approved endoluminal fundoplication technique which utilizes EsophyX device to restore the valve at the gastroesophageal junction. The EsophyX device (EndoGastric Solutions, Redmond, Wash, USA) is an FDA approved procedure for chronic of refractory GERD.
Study NCT05153499 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CP101
Description: CP101 is an investigational microbiome therapeutic designed to deliver a complete and functional microbiome to durably repair intestinal dysbiosis, which is being evaluated for the prevention of recurrent Clostridioides difficile infection (CDI).
Study NCT05153499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05568121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04RD1
Description: 1 tablet of L04RD1
Study NCT05568121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L04TD1
Description: 1 tablet of L04TD1
Study NCT04917861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1893
Description: Solution for injection
Study NCT04917861 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution for injection
Study NCT04917861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride solution for injection
Study NCT05854667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual plus Placebo
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.
Study NCT05854667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual plus Placebo plus Contingency Management
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.
Study NCT05854667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual plus lisdexamfetamine (LDX-01)
Description: Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15).
Study NCT05854667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management
Description: Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13.
Study NCT05295992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Varian Ethos Adaptive Radiation Therapy
Description: Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Study NCT05262439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New generation CPAP mask
Description: All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
Study NCT05828602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment
Study NCT05828602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeleRehabilitation
Description: TeleRehabilitation
Study NCT05221216 — intervention group
Intervention type: OTHER
Intervention: Collect data of medical record
Description: Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
Study NCT06407947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor modified T cells Infusion
Description: chimeric antigen receptor T cells
Study NCT05705492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO
Study NCT06489574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural with fentanyl in patients undergoing thoracotomy surgery
Description: A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group B:~Patients will receive 50 μg fentanyl in addition to 10 ml 0.125% bupivacaine followed by a continuous infusion (10 ml bupivacaine + 100 μg fentanyl + 38 ml saline with rate of 5 ml per hour).
Study NCT06319235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP
Description: DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.
Study NCT06319235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
Study NCT05303597 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasound-guided diagnostic nerve block with lidocaine
Description: Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
Study NCT05067946 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-19N
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen
Study NCT05067946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GX-19N formulation buffer
Study NCT06249490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
Study NCT06249490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
Study NCT06249490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06249490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride Injection
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT04476420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Description: Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.